SCHEMBL222587

SCHEMBL222587

Cc1ccc(OC(=O)C(C)(C)N)c(C(CCN(C(C)C)C(C)C)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.58
CHRM1 P11229 4/20 0.58
CHRM3 P20309 4/20 0.58
CHRM5 P08912 2/20 0.58
HRH1 P35367 2/20 0.58
LMNA P02545 1/20 0.58
ESR1 P03372 1/20 0.58
CHRM4 P08173 1/20 0.58
MAPT P10636 1/20 0.58
KCNE1 P15382 1/20 0.58
PTGS1 P23219 1/20 0.58
HRH2 P25021 1/20 0.58
HTR2A P28223 1/20 0.58
SLC6A4 P31645 1/20 0.58
ADRA1A P35348 1/20 0.58
OPRK1 P41145 1/20 0.58
KCNQ1 P51787 1/20 0.58
KCNH2 Q12809 1/20 0.58
CACNA1C Q13936 1/20 0.58
SCN5A Q14524 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877089 0.89 CHRM2 (0.61) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL574530 0.88 CHRM2 (0.67) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL4879639 0.88 CHRM2 (0.67) CHRM2CHRM1CHRM3CHRM5HRH1
Hydrochloric Acid SCHEMBL4771342 0.87 CHRM2 (0.66) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL725535 0.85 CHRM2 (0.77) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL13175653 0.85 CHRM2 (0.77) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL14709412 0.85 CHRM2 (0.77) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL222588 0.84 CHRM2 (0.62) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL2853537 0.84 CHRM2 (0.62) CHRM2CHRM1CHRM3CHRM5HRH1
SCHEMBL222314 0.84 CHRM2 (0.62) CHRM2CHRM1CHRM3CHRM5HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100112061-A1 Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis GILEAD SCIENCES, INC. 2010-05-06 US claimed
EP-2114972-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS Gilead Sciences, Inc. (US) 2009-11-11 EP claimed
WO-2008076269-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS GILEAD SCIENCES, INC. (US) 2008-06-26 WO claimed
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 US disclosed
EP-4346772-B1 PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES INC (US) 2026-04-01 EP disclosed
EP-4132651-B1 INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS GILEAD SCIENCES INC (US) 2026-03-18 EP disclosed
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES INC (US) 2026-02-05 US disclosed
US-12509466-B2 Methods and compounds for treating paramyxoviridae virus infections GILEAD SCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4107164-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 EP disclosed
US-12473314-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-11-18 US disclosed
EP-4644394-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2025-11-05 EP disclosed
US-20110124627-A1 MODULATORS OF TOLL-LIKE RECEPTORS GILEAD SCIENCES, INC. (US) 2011-05-26 US disclosed
WO-2011049825-A1 DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2011-04-28 WO disclosed
US-20110098248-A1 MODULATORS OF TOLL-LIKE RECEPTORS GILEAD SCIENCES, INC. (US) 2011-04-28 US disclosed
WO-2011031965-A1 MODULATORS OF TOLL-LIKE RECEPTORS GILEAD SCIENCES, INC. (US) 2011-03-17 WO disclosed
WO-2010077613-A1 MODULATORS OF TOLL-LIKE RECEPTORS GILEAD SCIENCES, INC. (US) 2010-07-08 WO disclosed
US-20100143301-A1 MODULATORS OF TOLL-LIKE RECEPTORS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
US-20100112061-A1 Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis GILEAD SCIENCES, INC. 2010-05-06 US disclosed
EP-2114972-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS Gilead Sciences, Inc. (US) 2009-11-11 EP disclosed
WO-2008076269-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS GILEAD SCIENCES, INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 CHRM2 1957/4885CHRM1 887/4885CHRM3 1090/4885
US-20110124627-A1 MODULATORS OF TOLL-LIKE RECEPTORS TLR3, TLR6, TLR1 CHRM2 2317/4885CHRM1 2763/4885CHRM3 1365/4885
US-20100143301-A1 MODULATORS OF TOLL-LIKE RECEPTORS TLR3, TLR2, TLR6 CHRM2 2340/4885CHRM1 3324/4885CHRM3 2136/4885
US-12509466-B2 Methods and compounds for treating paramyxoviridae virus infections MTAP, PNP, NSUN2 CHRM2 2054/4885CHRM1 1328/4885CHRM3 2104/4885
US-20110098248-A1 MODULATORS OF TOLL-LIKE RECEPTORS TLR3, TLR6, TLR1 CHRM2 2317/4885CHRM1 2763/4885CHRM3 1365/4885
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF PNP, SLC28A1, SLC29A1 CHRM2 1826/4885CHRM1 643/4885CHRM3 1953/4885
US-20100112061-A1 Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis ADRB1, ADRB2, CHRM3 CHRM2 5/4885CHRM1 4/4885CHRM3 3/4885
US-12473314-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 CHRM2 4750/4885CHRM1 4825/4885CHRM3 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.